Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus

Ain Shams University70 enrolled

Overview

This study included 70 subjects divided into 3 groups. Group I included 25 patients with NAFLD. Group II included 25 patients with NAFLD and chronic HCV. Group III: included 20 controls. Abdominal ultrasound was done to patients and controls. Plasma pentraxin-3 (PTX3) was measured using ELISA. Comparison between three groups was done regarding plasma pentraxin-3. Higher levels of plasma PTX3 were detected in NAFLD patients irrespective of presence or absence of chronic HCV infection. Plasma PTX3 could be used as a non-invasive test for prediction of metabolic syndrome in the high-risk population with high sensitivity and moderate specificity.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non Alcoholic Fatty Liver Disease

Interventions

plasma pentraxin-3DIAGNOSTIC_TEST

Plasma pentraxin-3 was measured using ELISA

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with NAFLD. * Patients with NAFLD and chronic hepatitis C viral infection. Exclusion Criteria: * Current or past consumption of significant amount of alcohol more than 21 drinks and 14 drinks per week for men and women respectively. * Patients receiving Drugs which cause fatty liver as amiodarone, diliazem, tamoxifen, steroids. * Patients who take statins as it has lowering effect on plasma PTX3. * Patients having any clinical evidence of hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding, elevated serum bilirubin level to more than two folds the upper limit of normal. * Patients with heart failure. * Patients with autoimmune rheumatic disease. * Patients with chronic kidney diseases. * Patients with sepsis.

Outcomes

Primary Outcomes

Plasma pentraxin-3 as a non invasive diagnostic marker in diagnosis of NAFLD in comparison to it's levels in patients with NAFLD and chronic hepatitis C viral infection

Measurement of plasma pentraxin-3 in patients with NAFLD in comparison to it's levels in patients with hepatic steatosis on top of HCV and normal controls

Time frame: 1 year